Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone

Holcombe E. Grier, Mark Krailo, Nancy J. Tarbell, Michael P. Link, Christopher Fryer, Douglas J. Pritchard, Mark C. Gebhardt, Paul S. Dickman, Elizabeth J. Perlman, Paul A. Meyers, Sarah S. Donaldson, Sheila Moore, Aaron R. Rausen, Teresa J. Vietti, James S. Miser

New England Journal of Medicine, 2003

Dana-Farber Cancer Institute, Harvard University, University of Southern California, Massachusetts General Hospital, Mayo Clinic in Arizona, Boston Children's Hospital, Children's Hospital of Pittsburgh, Johns Hopkins Hospital, Memorial Sloan Kettering Cancer Center, Radiation Oncology Associates, Children's Hospital of Los Angeles, Columbia University Irving Medical Center, New York University, Washington University Medical Center

Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

1321

Citations

View on Google Scholar

Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone

Abstract

Journal Details

Join JournalsHub

Welcome Back